Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / CCL18

CCL18

Basics

Aliases:
This biomarker is also known as:
  • DC-CK1,
  • small inducible cytokine subfamily A (Cys-Cys), member 18, pulmonary and activation-regulated,
  • pulmonary and activation-regulated chemokine,
  • MIP4,
  • Small-inducible cytokine A18,
  • alternative macrophage activation-associated CC chemokine 1,
  • DCCK1,
  • Alternative macrophage activation-associated CC chemokine 1,
  • MIP-4,
  • C-C motif chemokine 18,
  • chemokine (C-C), dendritic,
  • AMAC1,
  • Macrophage inflammatory protein 4,
  • AMAC-1,
  • CC chemokine ligand 18,
  • Pulmonary and activation-regulated chemokine,
  • CC chemokine PARC,
  • dendritic cell chemokine 1,
  • macrophage inflammatory protein 4,
  • chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated),
  • small inducible cytokine A18,
  • small-inducible cytokine A18,
  • SCYA18,
  • PARC,
  • CKb7,
  • Dendritic cell chemokine 1,

View in BioMuta

Description…

CCL18, also known as MIP-4, is a member of the cytokine family, a family of secreted proteins involved in immunoregulatory and inflammatory processes. CCL18 is a Cys-Cys (CC) cytokine, characterized by two adjacent cysteines. CCL18 is a chemotactic factor that attracts lymphocytes but not monocytes or granulocytes. This chemokine attracts naive T lymphocytes toward dendritic cells and activated macrophages in lymph nodes. It may play a role in both humoral and cell-mediated immunity responses.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: CCL18

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Lung

Attributes

Phase: Two
QA State: Curated

Overview

CCL18 has been described in the literature as a potential biomarker for ovarian, bladder, breast, and colorectal cancer. CCL18 has not been identified previously in serum as a lung cancer biomarker, but it was observed up-regulated in lung cancer in the aptamer proteomic technology study (Ostroff et al, 2010).

Performance Comment

CCL18, also known as MIP-4, is a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.

Prostate

Attributes

Phase: One
QA State: Under Review

Overview

Performance Comment

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh (ghoshjanjigias@mail.nih.gov) no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.